Excelsior BiopharmaROCO:6496 -1.63%50 Gross Margin % is 40.29% as of Dec. 2025, which is 8% above its 10-year median of 37.44. GuruFocus rates ROCO:6496 with a GF Score™ of 50/100 and a GF Value™ of NT$35.89 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, Excelsior Biopharma ranks worse than 64.81% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Excelsior Biopharma had a gross margin of 40.29% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Excelsior Biopharma Gross Margin % Related Terms
Excelsior Biopharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Excelsior Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Biopharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Excelsior Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Excelsior Biopharma (ROCO:6496) has a Gross Margin % of 40.29% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Excelsior Biopharma and its competitors. This is near median its historical median of 37.44. Over the past decade, Excelsior Biopharma's Gross Margin % has ranged from 21.48 to 44.33. According to the industry distribution chart, Excelsior Biopharma ranks #606 out of 935 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is Excelsior Biopharma's Gross Margin % too high?
Excelsior Biopharma's current Gross Margin % of 40.29% is near median its 10-year median of 37.44. Over the past 10 years, this metric has ranged from a low of 21.48 to a high of 44.33. The Drug Manufacturers industry median Gross Margin % is 48.46. Excelsior Biopharma's value of 40.29% is 16.9% below this industry median. Based on the distribution chart, Excelsior Biopharma ranks #606 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Excelsior Biopharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Excelsior Biopharma ranks #606 out of 935 companies for Gross Margin %. This places Excelsior Biopharma in the lower half of its industry. The industry median Gross Margin % is 48.46. Excelsior Biopharma's value of 40.29% is 16.9% below this benchmark. Historically, Excelsior Biopharma's own Gross Margin % has ranged from 21.48 to 44.33 over the past decade. While the company's 10-year median is 37.44 vs. the industry median of 48.46, Excelsior Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Excelsior Biopharma's current Gross Margin % of 40.29% is 16.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Excelsior Biopharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Biopharma's current Gross Margin % is 40.29%, which is near median its own 10-year median of 37.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Possible Value Trap. The stock's GF Value™ is NT$35.89, compared to a current price of NT$24.20 — trading 32.6% below its estimated fair value. The current Gross Margin % is 40.29%, which is near median its 10-year median of 37.44 and 16.9% below the Drug Manufacturers industry median of 48.46. Excelsior Biopharma's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current Gross Margin % is 40.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued.
The current stock price of NT$24.20 is trading 32.6% below its estimated GF Value™ of NT$35.89.
GuruFocus considers Excelsior Biopharma to be Possible Value Trap.
Key valuation signals for ROCO:6496:
Gross Margin %: 40.29% (near median its 10-year median of 37.44)
GF Value™: NT$35.89 vs. price of NT$24.20 (32.6% below fair value)
Industry Position: 16.9% below the Drug Manufacturers median (#606 of 935)
No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
50GF Score
Get the complete analysis for ROCO:6496
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6496 has been successfully added to your 
